Enriched clinical annotations |
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. |
Clinical annotation |
Category |
P-value |
Hits |
Hits(%) |
Module hits in category |
Arrays in annotation |
Arrays |
Lung cancer (General compendium) |
General compendium |
2.0e-11 |
28 |
47.4 |
59 |
244 |
1946 |
Non small cell lung cancer (General compendium) |
General compendium |
1.1e-10 |
25 |
42.3 |
59 |
205 |
1946 |
Lung cancer or cell line (General compendium) |
General compendium |
1.2e-10 |
28 |
47.4 |
59 |
262 |
1946 |
Non small cell lung cancer and cell line (General compendium) |
General compendium |
7.4e-10 |
25 |
42.3 |
59 |
223 |
1946 |
Lung tissue, cancer or cell line (General compendium) |
General compendium |
8.4e-10 |
29 |
49.1 |
59 |
304 |
1946 |
Cancer and cell line (General compendium) |
General compendium |
8.8e-09 |
59 |
100 |
59 |
1429 |
1946 |
Acute lymphocytic leukemia (General compendium) |
General compendium |
6.1e-07 |
14 |
23.7 |
59 |
99 |
1946 |
Bone marrow (Leukemia) |
Leukemia |
1.2e-06 |
10 |
71.4 |
14 |
23 |
141 |
B cells (Leukemia) |
Leukemia |
4.0e-06 |
14 |
100 |
14 |
62 |
141 |
Cancer (General compendium) |
General compendium |
1.5e-05 |
49 |
83.0 |
59 |
1110 |
1946 |
Normal breast tissue (Breast cancer) |
Breast cancer |
2.3e-05 |
4 |
57.1 |
7 |
6 |
152 |
Normal female hormonal tissue (Breast cancer) |
Breast cancer |
2.3e-05 |
4 |
57.1 |
7 |
6 |
152 |
Normal tissue (Breast cancer) |
Breast cancer |
2.3e-05 |
4 |
57.1 |
7 |
6 |
152 |
Adenocarcinoma (General compendium) |
General compendium |
5.3e-05 |
28 |
47.4 |
59 |
466 |
1946 |
Enriched GO annotations |
For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). |
GO annotation |
P-value |
Hits |
Hits(%) |
Module genes |
Genes in annotation |
Genes |
G-protein signaling\, coupled to cAMP nucleotide second messenger |
5.2e-19 |
10 |
71.4 |
14 |
39 |
4609 |
cAMP-mediated signaling |
1.5e-17 |
9 |
64.2 |
14 |
31 |
4609 |
G-protein signaling\, coupled to cyclic nucleotide second messenger |
3.5e-17 |
10 |
71.4 |
14 |
57 |
4609 |
adenylate cyclase activation |
3.8e-13 |
6 |
42.8 |
14 |
13 |
4609 |
G-protein signaling\, adenylate cyclase activating pathway |
1.1e-12 |
6 |
42.8 |
14 |
15 |
4609 |
G-protein coupled receptor protein signaling pathway |
2.5e-12 |
11 |
78.5 |
14 |
246 |
4609 |
toxin activity |
1.8e-09 |
4 |
28.5 |
14 |
7 |
4609 |
intracellular signaling cascade |
1.8e-09 |
10 |
71.4 |
14 |
322 |
4609 |
G-protein coupled receptor activity |
7.2e-09 |
8 |
57.1 |
14 |
170 |
4609 |
rhodopsin-like receptor activity |
8.2e-08 |
7 |
50 |
14 |
147 |
4609 |
cell communication |
9.8e-07 |
12 |
85.7 |
14 |
1043 |
4609 |
signal transduction |
1.4e-06 |
11 |
78.5 |
14 |
841 |
4609 |
negative regulation of adenylate cyclase activity |
2.6e-06 |
3 |
21.4 |
14 |
10 |
4609 |
conjugation without cellular fusion |
2.9e-06 |
6 |
42.8 |
14 |
153 |
4609 |
G-protein signaling\, coupled to IP3 second messenger (phospholipase C activating) |
9.6e-06 |
4 |
28.5 |
14 |
48 |
4609 |
G-protein signaling\, adenylate cyclase inhibiting pathway |
1.2e-05 |
3 |
21.4 |
14 |
16 |
4609 |
signal transducer activity |
1.2e-05 |
11 |
78.5 |
14 |
1035 |
4609 |
transmembrane receptor activity |
1.3e-05 |
8 |
57.1 |
14 |
449 |
4609 |
cell surface receptor linked signal transduction |
6.0e-05 |
6 |
42.8 |
14 |
259 |
4609 |
receptor activity |
9.5e-05 |
8 |
57.1 |
14 |
585 |
4609 |